Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference
Dominik Linz,Jason G Andrade,Elena Arbelo,Giuseppe Boriani,Guenter Breithardt,A John Camm,Valeria Caso,Jens Cosedis Nielsen,Mirko De Melis,Tom De Potter,Wolfgang Dichtl,Søren Zoega Diederichsen,Dobromir Dobrev,Nicolas Doll,David Duncker,Elke Dworatzek,Lars Eckardt,Christoph Eisert,Larissa Fabritz,Michal Farkowski,David Filgueiras-Rama,Andreas Goette,Eduard Guasch,Guido Hack,Stéphane Hatem,Karl Georg Haeusler,Jeff S Healey,Hein Heidbuechel,Ziad Hijazi,Lucas H Hofmeister,Leif Hove-Madsen,Thomas Huebner,Stefan Kääb,Dipak Kotecha,Katarzyna Malaczynska-Rajpold,José Luis Merino,Andreas Metzner,Lluís Mont,Ghulam Andre Ng,Michael Oeff,Abdul Shokor Parwani,Helmut Puererfellner,Ursula Ravens,Michiel Rienstra,Prashanthan Sanders,Daniel Scherr,Renate Schnabel,Ulrich Schotten,Christian Sohns,Gerhard Steinbeck,Daniel Steven,Tobias Toennis,Stylianos Tzeis,Isabelle C van Gelder,Roderick H van Leerdam,Kevin Vernooy,Manish Wadhwa,Reza Wakili,Stephan Willems,Henning Witt,Stef Zeemering,Paulus Kirchhof
DOI: https://doi.org/10.1093/europace/euae070
2024-03-30
Abstract:Aims: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Methods and results: Eighty-three international experts met in Münster for 2 days in September 2023. Key findings are as follows: (i) Active rhythm management should be part of the default initial treatment for all suitable patients with AF. (ii) Patients with device-detected AF have a low burden of AF and a low risk of stroke. Anticoagulation prevents some strokes and also increases major but non-lethal bleeding. (iii) More research is needed to improve stroke risk prediction in patients with AF, especially in those with a low AF burden. Biomolecules, genetics, and imaging can support this. (iv) The presence of AF should trigger systematic workup and comprehensive treatment of concomitant cardiovascular conditions. (v) Machine learning algorithms have been used to improve detection or likely development of AF. Cooperation between clinicians and data scientists is needed to leverage the potential of data science applications for patients with AF. Conclusions: Patients with AF and a low arrhythmia burden have a lower risk of stroke and other cardiovascular events than those with a high arrhythmia burden. Combining active rhythm control, anticoagulation, rate control, and therapy of concomitant cardiovascular conditions can improve the lives of patients with AF.